NasdaqGM:CRSPBiotechs
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story
ARK Investment Management has significantly expanded its position in CRISPR Therapeutics (NasdaqGM:CRSP), purchasing a large block of shares.
The move highlights ARK's confidence in CRISPR Therapeutics' role in gene editing and its clinical pipeline.
The news coincides with continued work on gene editing therapies targeting beta thalassemia, sickle cell disease, cardiovascular conditions, and type 1 diabetes.
CRISPR Therapeutics' share price recently stood at $49.96, with the stock showing...